TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05927532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argyle Safety Fistula Cannula with Anti-Reflux Valve
Description: The Argyle Safety Fistula Cannula with Anti-reflux Valve will be used 3x a week for 12 weeks in subjects with an arteriovenous fistulae (AVF) fistula
Study: NCT05093374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-VEGF agent
Description: All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-VEGF agent
Description: All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment.
Study: NCT06210516

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PowerBreathe
Description: Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Primary Outcome Measurement:~1. Maximal Inspiratory Pressure (MIP)~Secondary Outcome Measurements:~1. Chest circumference measurements~2. Diaphragm movements and thickness (ultrasound)~3. Hand grip strength (with a Jamar hand dynamometer)~4. Motor Activity Log~5. 6 Minute Walk Test (6MWT)~6. Canadian Occupational Performance Measure~7. Charlson Comorbidity Index
Study: NCT06493188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fidelity interprofessional simulation
Description: Students will participate in realistic (high-fidelity) interprofessional simulation scenarios to practice and interpret ABG procedures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fidelity interprofessional simulation
Description: Students will take part in low-fidelity interprofessional simulation scenarios. Cases will be discussed, and reflection on ABG execution and interpretation will be guided using paper descriptions and clinical files
Study: NCT06238128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid Rapid Resonse System (ORRS) training
Description: ORRS is on online system to train citizen responders to administer NARCAN to save the lives of opioid overdose victims. It capitalizes on the innovative PulsePoint technology to connect responders to overdose events. PulsePoint is an app that connects 911 requesting assistance for cardiac arrests to responders with Cardiopulmonary Resuscitation (CPR) training. ORRS allows us to partner with PulsePoint users to expand its reach to opioid overdoses, which share the need for a quick response that emergency responders are often unable to provide. ORRS has the advantage of expanding the population of responders with NARCAN, rescue breathing, and CPR training that can be connected to overdose events, increasing the likelihood of saving overdose victims' lives through a quick, efficient response. ORRS is delivered through an interactive, digital platform containing sequential, multi-media modules.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Non-active opioid overdose response training
Description: Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training.~Once the project is completed, participants will receive online Naloxone training.
Study: NCT03911739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Injection
Description: Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Sublingual Product
Description: Sublingual buprenorphine (BUP-SL), administered daily.
Study: NCT06030947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced Flap combined with a Connective Tissue Graft
Description: Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with a connective tissue graft harvested from the palate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap combined with micro Connective Tissue Graft
Description: Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with multiple micro connective tissue graft harvested from the palate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Division of the Connective Tissue Graft into multiple micro Connective Tissue Grafts
Description: The harvested connective tissue graft is divided in multiple micro connective tissue grafts with a scalpel blade before being placed on the recipient site.
Study: NCT05329155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Sodium Injection
Description: Heparin Sodium Injection (100U/Kg body weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Sodium Injection
Description: Heparin Sodium Injection (100U/Kg body weight)
Study: NCT06406894

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: lower limb muscle stretching ( pelvic bridging, Knee to chest,cat and camel stretch) (30 seconds hold and 3 sets of 5 repetitions with 1 min rest interval in between each set, per session on daily basis for only one week for immediate results and for long term effect on alternate 3 days in remaining 2nd ,3rd week).~Treatment protocol will be given on daily basis to check immediate effect and for long term effect treatment will be given in alternating 3 days for remaining 2 weeks. Total 12 session were given (3 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Superficial back line relaxation (SMIT & CCFE)
Description: Experimental group was given superficial back line relaxation includes SMIT \& CCFE along with conventional therapy includes lower limb muscle stretching. SMIT For short term effect 10-12 repetitions per session, on daily basis for 1st week. For long term effect 10-12 repetitions per session, for 3 alternate days in remaining 2nd\&3rd week. CCFE For short term effect 3 sets of 10 reps , 10 sec hold , 1 min rest after each set, on daily basis for 1st week. For long term effect 3 sets of 10 reps, 10 sec hold , 1 min rest after each set, for 3 alternate days , remaining 2nd \& 3rd week. Conventional therapy lower limb muscle stretching ( For short term effect 30 seconds hold , 3 sets of 5 repetitions , 1 min rest after each set, per session on daily basis for 1st week , for long term effect on alternate 3 days in remaining 2nd ,3rd week). Total 12 sessions were given (3 weeks).
Study: NCT06460298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Levels (DL) 1,2,3,4
Description: ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAgio Dose Expansion
Description: ProAgio combined with Gemcitabine in patients with metastatic TNBC who have been previously treated with at least two prior lines of therapy.
Study: NCT05808699

Intervention type: DEVICE
Intervention: handheld fundus camera
Description: Fundus camera
Study: NCT06173713

Intervention type: DEVICE
Group type: OTHER
Intervention: Emphasys Hip Solutions
Description: Emphasys Acetabular Shell, Emphasys AOX Polyethylene Liner, Articul/eze 12/14 metal head and Emphasys fem. stem
Study: NCT06371911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cureety telemonitoring
Description: The digital telemonitoring platform, Cureety, has been designed to facilitate the monitoring of signs and symptoms of treatment-specific AEs and disease progression. The platform integrates Cureety TechCare, a CE marked algorithm that is a class I medical device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPTIMA or equivalent programs
Description: The programs consist of three stages:~1. The medical team make structured telephone calls with patients 2 to 3 days before the planned administration of injectable treatment. Adverse events and other relevant data are collected.~2. Patients undergo biological tests within 48 hours of the appointment and the results are sent by the laboratory to the centre.~3. Then, the physician assesses the data and decides whether to anticipate and validate the prescription of injectable treatments.
Study: NCT05004181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent BNT162b2 (B.1.1.7)
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent BNT162b2 (B.1.617.2)
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent BNT162b2 (B.1.617.2)
Description: Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent BNT162b2 (B.1.1.529.1)
Description: Intramuscular (IM)

Intervention type: OTHER
Group type: OTHER
Intervention: Observational
Description: No vaccination within 3 months after Visit 1.
Study: NCT06651879

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: techniques of ultrasound examination of the airway
Description: two different techniques of ultrasound. The techniques are the two views and the five views

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: techniques of ultrasound examination of the airway
Description: two different techniques of ultrasound. The techniques are the two views and the five views
Study: NCT06649825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B1
Description: Vitamin B1 tablets, 100mg bid, taken orally for one year
Study: NCT05334108

Intervention type: DRUG
Group type: OTHER
Intervention: Ecopipam
Description: ecopipam HCl \~2mg/kg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Ecopipam
Description: ecopipam HCl \~2mg/kg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Ecopipam
Description: ecopipam HCl \~2mg/kg/day

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 1 Probe Substrate Cocktail
Description: dextromethorphan, caffeine, omeprazole, and midazolam

Intervention type: DRUG
Group type: OTHER
Intervention: Cohort 2 Probe Substrate
Description: bupropion

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cohort 3 Probe Substrate Cocktail
Description: dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
Study: NCT05544968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
Description: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
Study: NCT06535009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7914
Description: Specified dose on specified days
Study: NCT06649799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LenSx
Description: The patients in Group 1 conduct FLACS under LenSx
Study: NCT06535009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7914
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days
Study: NCT06649799

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Z8
Description: The patients in Group 1 conducted FLACS using Z8
Study: NCT06652620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cola
Description: regular Coca-Cola (Coca-Cola company, Atlanta, GA) or Pesi-cola (PepsiCo, Inc.New York, NY)
Study: NCT06652685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D5-PBCR(-) IA arm
Description: Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D5-PBCR(+) IA+Venetoclax arm
Description: Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status.
Study: NCT06652347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer care delivery
Description: Early vs. delayed sharing of GA and OFS diagnostic results and how that sharing affects patient preferences, decision- making, and satisfaction in the context of participants' cancer care.
Study: NCT05303727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Thymocyte Globulin
Description: 2.5 mg/kg/day；2 doses on day -3 and day -2 for matched sibling donor transplantation；3 doses on day -4，-3 and day -2 for unrelated donor transplantation；4 doses on day -5，-4，-3 and day -2 for haploidentical donor transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide injection
Description: 60 mg/kg/day for 2 days in cord blood stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 2mg/m2/day for 3 days in cord blood stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70mg/m2/day，for peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation；2 doses on day -3 and day -2 when conditioning regimen containing thiotepa；3 doses on day -4，-3 and day -2 when conditioning regimen not containing thiotepa；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/day for 2 days in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8mg/kg/dose；8 doses in cord blood stem cell transplantation；12 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen containing thiotepa；16 doses in peripheral stem cell transplantation or haploidentical bone marrow combined with peripheral stem cell transplantation when conditioning regimen not containing thiotepa；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 2.5\~4 mg/kg/dose every 12 hours orally；1.5\~2 mg /kg/dose every 12 hours intravenously; trough concentration maintained at 150\~250ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.02\~0.03 mg/kg/day as continuous infusion or 12 hour divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg/dose every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg/m2/dose on d+1 and 10 mg/m2/dose on d+3，d+6 in peripheral stem cell transplantation
Study: NCT05103410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARIPiprazole 30 MG
Description: Patients will receive Aripiprazole 30 mg tablet orally 3 h before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo tablet which is identical in appearance, size, shape, and color to aripiprazole 3 h before surgery
Study: NCT05164562

Intervention type: OTHER
Intervention: Data collection
Description: Description: musculoskeletal disorders of upper limb evaluation
Study: NCT05005130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TASKPEN
Description: TASKPEN is the name of the package of implementation strategies proposed by the investigators that are intended to deliver the WHO PEN intervention in routine HIV clinical practice settings in Zambia. TASKPEN has five components which will be the subject of stakeholder consultation and adaptation in this formative research protocol. The package of integrated HIV/NCD services includes:~1. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~2. Access to cardio-metabolic condition screening \& laboratory monitoring~3. Non communicable disease-focused electronic medical record module~4. Integrated non-communicable/HIV care (one stop shop for services)~5. Strengthened non-communicable disease (NCD) medication supply chain, including multi-month dispensing (MMD)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TASKPEN
Description: TASKPEN is the name of the package of implementation strategies proposed by the investigators that are intended to deliver the WHO PEN intervention in routine HIV clinical practice settings in Zambia. TASKPEN has five components which will be the subject of stakeholder consultation and adaptation in this formative research protocol. The package of integrated HIV/NCD services includes:~1. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~2. Access to cardio-metabolic condition screening \& laboratory monitoring~3. Non communicable disease-focused electronic medical record module~4. Integrated non-communicable/HIV care (one stop shop for services)~5. Strengthened non-communicable disease (NCD) medication supply chain, including multi-month dispensing (MMD)
Study: NCT04917198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: median sternotomy
Description: median sternotomy
Study: NCT06520748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand rehabilitation program using the computerized glove
Description: The patient extended finger to reach from grey to green to red colour and heard the beep providing knowledge of result (KR), whereas the increase of range of finger extension reached every session provides knowledge of performance (KP). As the patient's performance improved, the range of their finger's movement will also be increased due to the augmented feedback provided to the patient and the therapist through the glove software

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected hand program
Description: Distal key point of Bobath, approximation of affected arm, to control spasticity of wrist/ finger flexor (5 minutes). Dynamic splint to facilitate wrist and finger extension (10 repeat\*5 sets). Passive range of motion exercise (10 repeat\*5 sets) for each joint. Mud exercise (spherical, clyndrical , hook). Thera band exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected hand program
Description: Distal key point of Bobath, approximation of affected arm, to control spasticity of wrist/ finger flexor (5 minutes). Dynamic splint to facilitate wrist and finger extension (10 repeat\*5 sets). Passive range of motion exercise (10 repeat\*5 sets) for each joint. Mud exercise (spherical, clyndrical , hook). Thera band exercises.
Study: NCT06536010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；
Description: VAG in the induction phase of the ND-AML treatment protocol
Study: NCT05239026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced treadmill walking
Description: Participants will walking on a treadmill for 6 5-minute Blocks. The cadence will be progressively reduced for the first 3 Blocks. Speed will progressively increase during Blocks 4-6 while cadence from Block 3 is maintained.
Study: NCT06059547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Biological, monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Biological, monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visugromab (CTL-002)
Description: Biological, monoclonal antibody